Figure 4.

Relationship between relative miR-155 expression levels in plasma and response to treatment in patients in groups D and E. Relative expression levels of miR-155 in plasma were significantly higher in patients who achieved a complete response than in patients who experienced other types of clinical responses. (A) Patients who received fludarabine, cyclophosphamide, and rituximab as salvage therapy (group D). (B) Patients treated with lenalidomide (group E). The miRNA expression levels were unavailable for 7 patients (“Materials and methods”). Raw data for all plasma samples are shown in supplemental Table 4.